VEGFA and neoplasm: Angiogenic markers such as CD31 expression, microvessel density, and tumor VEGF-A levels were identified in a retrospective analysis of the GOG 218 study as potential predictive and prognostic biomarkers of response to anti-angiogenic therapy [105].